Skip to Content
Merck

740063

Chitosan

Mv 60,000-120,000

Synonym(s):

KiOmedine-CsU® B, Deacetylated chitin, Poly(D-glucosamine)

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

CAS Number:
9012-76-4
UNSPSC Code:
12352201
MDL number:
MFCD00161512

Product Name

Chitosan, Mv 60,000-120,000

InChI

1S/C56H103N9O39/c1-87-56(86)65-28-38(84)46(19(10-74)96-55(28)104-45-18(9-73)95-49(27(64)37(45)83)97-39-12(3-67)88-47(85)20(57)31(39)77)103-54-26(63)36(82)44(17(8-72)94-54)102-53-25(62)35(81)43(16(7-71)93-53)101-52-24(61)34(80)42(15(6-70)92-52)100-51-23(60)33(79)41(14(5-69)91-51)99-50-22(59)32(78)40(13(4-68)90-50)98-48-21(58)30(76)29(75)11(2-66)89-48/h11-55,66-85H,2-10,57-64H2,1H3,(H,65,86)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48+,49+,50+,51+,52+,53+,54+,55+/m1/s1

InChI key

FLASNYPZGWUPSU-SICDJOISSA-N

biological source

white mushroom

mol wt

Mv 60,000-120,000

composition

Bacterial endotoxins, ≤10 EU/g
Beta-glucan, ≤5 % (w/w)
Chitosan, ≥93 % (w/w)
Proteins, ≤1 % (w/w)

viscosity

5-200 mPa.s (1% solution in 1% HAc)

solubility

acetic acid: 1% (solution)

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Application

Forms gels with multivalent anions. Gives clear solutions that dry to strong, clear films.
Ideal for wound healing and hemostasis; biosurgery and ophthalmology; scaffold and cell therapy; and drug delivery and vaccines

Features and Benefits

Biocompatible, antibacterial and environmentally friendly polyelectrolyte with a variety of applications including water treatment, chromatography, additives for cosmetics, textile treatment for antimicrobial activity, novel fibers for textiles, photographic papers, biodegradable films, biomedical devices, and microcapsule implants for controlled release in drug delivery.
Biocompatible, antibacterial and environmentally friendly polyelectrolyte.

General description

Degree of acetylation: ≤40 mol. %
KiOmedine®-CsU is an ultra-pure chitosan of non-animal origin, produced from white mushrooms (Agaricus bisporus), in accordance with cGMP.
The crystalline structure is in the α-form. The linkage between glucosamine units is β-(1,4).

Legal Information

Product of KitoZyme
KiOmedine is a registered trademark of KitoZyme, S.A.

Storage Class

11 - Combustible Solids

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
STBD5952V
STBD5374V
STBD1418V
STBD1273V
STBC9906V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chitosan-based Biomaterials."Innovative Polymers Engineered for Drug Delivery and Tissue Engineering
Wu G, et al.
Material Matters, 7(3) null
Liming Hu et al.
Nanoscale, 5(8), 3103-3111 (2013-03-22)
Within the past few years, chitosan-based drug delivery vehicles have become some of the most attractive to be studied. In contrast to all other polysaccharides, chitosan has demonstrated its unique characteristics for drug delivery platforms, including its active primary amino
William D Stanish et al.
The Journal of bone and joint surgery. American volume, 95(18), 1640-1650 (2013-09-21)
Microfracture, the standard of care, is recognized to be an incomplete solution for cartilage damage. BST-CarGel, a chitosan-based medical device, is mixed with autologous whole blood and is applied to a microfractured cartilage lesion in which it physically stabilizes the
Alberto Busilacchi et al.
Carbohydrate polymers, 98(1), 665-676 (2013-08-31)
The idea of using chitosan as a functional delivery aid to support simultaneously PRP, stem cells and growth factors (GF) is associated with the intention to use morphogenic biomaterials to modulate the natural healing sequence in bone and other tissues.
Bijay Singh et al.
Journal of nanoscience and nanotechnology, 14(1), 564-576 (2014-04-16)
Successful gene therapy depends on the development of efficient and cell-specific gene delivery systems. Currently, animal viral vectors have been mostly used for in vivo and in clinical trials owing to their high transduction efficiency. However, they suffer from numerous
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service